The Time Has Come: 4 Gene Therapy Stocks to Buy, 1 to Avoid


It’s a big day for gene therapy. A panel of independent FDA advisors is meeting today to consider the merits of Luxturna, a one-time gene therapy developed by Spark Therapeutics (ONCE) meant to treat a rare form of childhood blindness. If the panel votes to recommend the drug’s approval, and the FDA …

Spark gene therapy improves vision, at least in short term: FDA

(Reuters) – Spark Therapeutics Inc’s experimental gene therapy for a rare inherited form of blindness improves vision, though it is unclear whether the benefit lasts over time, according to a preliminary review by the U.S. Food and Drug Administration. The therapy, Luxturna, or voretigene neparvovec, would be the first-ever gene …

FDA Panel Mulls Gene Therapy for Kids With Rare Eye Disease

THURSDAY, Oct. 12, 2017 (HealthDay News) — A U.S. Food and Drug Administration advisory panel was poised on Thursday to recommend approval for a gene therapy that could grant the gift of sight to young people with a rare type of inherited vision loss.Replacing a nonworking gene with a new …

FDA To Advisors: What If One-Time Gene Therapy Needs Extra Doses?

Xconomy National —  In the run-up to a key vote on an experimental gene therapy, the FDA raised no major flags about the drug’s track record but said its long-term effect remains an open question. That question should receive a thorough airing Thursday, when a meeting of FDA outside advisors …

FDA Approves First Gene Therapy Treatment For Cancer

The Food and Drug Administration Wednesday announced what the agency calls a “historic action” — the first approval of a gene therapy in the United States. The FDA approved Kymriah, which scientists refer to as a “living drug” because it involves FDA approval brings first gene therapy to the United …

The Latest: FDA advisers endorse gene therapy for blindness

Dr. Barry Byrne listens to testimony concerning the approval of a potentially breakthrough drug for a form of blindness during a meeting of the The Cellular, Tissue and Gene Therapies advisory committee, Thursday, Oct. 12. 2017, at the FDA in Silver Spring, Md. (Nick Wass/Associated Press) By Associated Press By …

FDA advisers review gene therapy to treat form of blindness

By Associated Press By Associated Press October 12 at 10:12 AM SILVER SPRING, Md. — U.S. health advisers are reviewing a novel treatment for a rare form of inherited blindness, potentially setting the stage for the launch of a groundbreaking new genetic medicine. The Food and Drug Administration panel will …

Spark’s Gene Therapy to Treat Blindness Gets Closer to Approval

A treatment that can stop patients from going blind is poised to be the first gene therapy for an inherited condition approved in the U.S., in what would be a major scientific milestone — and also open the door for record-breaking drug prices and novel ways to pay for them.Spark …